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Reply to the Editor: 
We thank Dr. Edmunds for his comments on our data 
and insights. We totally agree with his opinion that the 
systemic aprotinin remains a proven method to preserve 
hemostasis and that subsequent s udies of topical aproti- 
nin are needed to confirm the efficacy and reveal the 
mechanism of preserving hemostasis during and after 
cardiopulmonary b pass (CPB). 
When comparing advantages of two protocols of sys- 
temic aprotinin (high-dose and low-dose), however, we 
are faced with two specific questions: Is the inhibition of 
kallikrein activity needed uring CPB to preserve hemo- 
stasis? Is the fibrinolysis inhibition in the systemic blood 
needed after the end of CPB? The katlikrein activity, 
which is significantly inhibited by the high-dose protocol 
and not by the low-dose protocol, could accelerate the 
intrinsic clotting system as pointed out by Dr. Edmunds, 
consequently activating and damaging platelets by throm- 
bin generation 1 during CPB. Although some reports 2 
indicated that high-dose aprotinin significantly reduced 
clotting activity during CPB, a recent study 3showed that 
the predominant clotting activity is generated through the 
extrinsic pathway, which is in accordance with our obser- 
vation in the pericardial cavity. 4 Thus activation of the 
kallikrein system is probably of minor importance for 
thrombin generation during CPB. These conflicting re- 
sults make the clinical relevance of kallikrein inhibition on 
preserving hemostasis questionable. The second conflict- 
ing point is the importance of fibrinolysis inhibition in the 
systemic blood after CPB on preserving hemostasis, which 
could be achieved only by the high-dose protocol. Our 
previous tudy s demonstrated that fibrinolysis timulating 
activity is locally intensified inside the thoracic avity after 
operation, which is quite in contrast to the rapidly disap- 
pearing activity in the systemic blood after CPB. These 
data suggest that hemostatic fibrin sealing on the wound 
surface could be attacked by fibrinolysis more from the 
side of the wound surface than of systemic blood after 
CPB. According to this speculation, the topical use of 
aprotinin on the surgical wound at the end of operation 
makes ense, and the importance of maintaining systemic 
high concentrations of aprotinin after CPB has been 
challenged. 
As stated by Dr. Edmunds, nothing is ever simple in the 
hemostatic mechanism of patients after CPB. Every find- 
ing will give us a clue to reveal the mechanism of 
hemostasis and improve therapy. 
N. Tabuchi, MD 
W. van Oeveren, PhD 
Thoraxcenter 
Blood Interaction Research 
University Hospital 
Oostersinget 59 
9713 EZ Groningen, The Netherlands 
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The location of station 11 pulmonary lymph nodes 
To the Editor: 
Anatomically, station 11 pulmonary lymph nodes are 
described by Naruke 1 as intertobar and are present be- 
tween the lobar bronchi n either lung. These nodes are 
originally described by Rouvi6re 2as being present in the 
angle between the upper and middle lobe bronchi on the 
right. These were termed the "superior interlobar nodes." 
The "inferior intertobar nodes" are located below the 
middle lobe bronchus, lie between it and the lower lobe 
bronchus, and are also referred to as station t l  lymph 
nodes. In the left lung the lymph nodes in station 11 lie in 
the angle between the left upper lobe and lower lobe 
bronchi. Rouvi6re 2termed these nodes the "left interlo- 
bar lymph nodes." Borrie 3 referred to these superior 
interlobar nodes as the "sump nodes" of the right lung 
and the interlobar nodes as the sump nodes of the left 
lung. It is thus difficult to accept inclusion of the lymph 
nodes of station 11 as being hilar nodes, which are 
typically described as being along either main stem bron- 
chus. Unfortunately, Yano and his colleagues 3 have con- 
sidered station 1t nodes as hilar nodes in their recent 
publication. Unless these aforementioned authors have a 
compelling, rational explanation for the inclusion of the 
nodes of station 11 with those of station 10 as hilar nodes, 
the data generated as to the difference in survival and sites 
of recurrence between those patients with metastatic 
involvement of "hilar" nodes and those patients with only 
"lobar" (stations 12 and 13) nodal involvement cannot be 
accepted without serious reservation. 
Thomas W. Shields, MD 
Professor Emeritus of Surgery 
Northwestern University Medical School 
Chicago, IL 60611-2950 
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